Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm dinutuximab + GM-CSF + IL-2 immunotherapy study in high-risk neuroblastoma
2013-004864-69Phase 2Active
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dinutuximab in neuroblastoma, sponsored by Fundació Sant Joan de Déu. Primary endpoint: Safety and toxicities. Started Apr 2014; status: active.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2013-004864-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004864-69.